As immuno-oncology takes center stage in the battle against cancer, the need for biomarkers has become even more acute, with response rates continuing in the 20%–30% range and the menu of options, including combination therapies, growing at an accelerating pace. The specific immunoarchitecture characteristics of the microenvironment in which a particular tumor grows may be both prognostic and predictive of response to these new immunotherapies. Multiplex immunofluorescence is the most effective, efficient way to identify specific immune cell types, their location, and their state of activation, as well as the presence of immunoactive molecular expression, all at the same time. This method is highly beneficial for exploring immune evasion mechanisms and finding potential biomarkers that allow researchers to assess the mechanism of action and predict and track response. This live, online seminar will take the viewer through validation of this multiplexing technique, including a comparison with singleplex immunofluorescence and standard (chromogenic) immunohistochemistry, as well as an assessment of intersite reproducibility and the influence of staining order on quantitation.
During the webinar, the viewers will:
- Gain a clearer understanding of multiplex immunofluorescence and how it compares with singleplex and current immunohistochemical techniques
- See experimental evidence of the real-world application of multiplexing and how it can be applied to study the tumor microenvironment.
The webinar will last approximately 60 minutes.
To learn more about products or technologies related to this webinar, go to: www.perkinelmer.com/cancer-immunology/